Q: Which of the following is NOT part of the Fibrosis-4 (FIB-4) Index in liver diseases?
A) Age
B) ALT
C) AST
D) Bilirubin
E) Platelets
Answer: D
MASLD was previously known as nonalcoholic fatty liver disease (NAFLD). The FIB-4 score is used to assess fibrosis and cirrhosis. It applies to patients aged 35 and older. It is based on the formula:
FIB-4 = Age * AST / (0.001 * Platelets * sqr(ALT))
The formula uses US units.
Cutoff values for suspecting liver fibrosis vary by study and by the etiology of liver disease. The FIB-4 index Risk:
- <1.3 = Advanced fibrosis/cirrhosis less likely
- ≥1.3 and ≤2.67 = Indeterminate
- >2.67 = Advanced fibrosis/cirrhosis more likely
FIB-4 index is found to have a good predictive accuracy for advanced fibrosis, particularly in patients with chronic Hepatitis C (HCV) and in patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), which was previously known as nonalcoholic fatty liver disease (NAFLD), where the area under the ROC curve for predicting adverse liver-related outcomes was 0.81 and for predicting death or liver transplantation was 0.67.
FIB-4 values have also been associated with the risk of developing hepatocellular carcinoma (HCC) in alcoholic patients, where it is used in correlation with the level of alcohol consumption.
#hepatology
References:
1. Angulo P, Bugianesi E, Bjornsson ES, et al. Simple noninvasive systems predict long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology 2013; 145:782.
2. Vallet-Pichard A, Mallet V, Nalpas B, et al. FIB-4: an inexpensive and accurate marker of fibrosis in HCV infection. comparison with liver biopsy and fibrotest. Hepatology 2007; 46:32.
3. Suh B, Yun JM, Park S, et al. Prediction of future hepatocellular carcinoma incidence in moderate to heavy alcohol drinkers with the FIB-4 liver fibrosis index. Cancer 2015; 121:3818.
4. Sterling RK, Patel K, Duarte-Rojo A, et al. AASLD Practice Guideline on blood-based noninvasive liver disease assessment of hepatic fibrosis and steatosis. Hepatology 2025; 81:321.
1>